|
1
|
CBTRUS: CBTRUS Statistical report: Primary
brain and central nervoussystem tumors diagnosed in the United
States in 2004–2007. Source: Central Brain Tumor Registry of the
United States. CBTRUS; Hindsdale, IL, USA: 2011, http://www.cbtrus.orgurisimplewww.cbtrus.org.
|
|
2
|
Stupp R, Mason WP, van den Bent MJ, et al
European Organisation for Research and Treatment of Cancer Brain
Tumor and Radiotherapy Groups; National Cancer Institute of Canada
Clinical Trials Group: Radiotherapy plus concomitant and adjuvant
temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stupp R, Hegi ME, Mason WP, et al European
Organisation for Research and Treatment of Cancer Brain Tumour and
Radiation Oncology Groups; National Cancer Institute of Canada
Clinical Trials Group: Effects of radiotherapy with concomitant and
adjuvant temozolomide versus radiotherapy alone on survival in
glioblastoma in a randomised phase III study: 5-year analysis of
the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fukushima T, Takeshima H and Kataoka H:
Anti-glioma therapy with temozolomide and status of the DNA-repair
gene MGMT. Anticancer Res. 29:4845–4854. 2009.PubMed/NCBI
|
|
5
|
Sharma S, Salehi F, Scheithauer BW,
Rotondo F, Syro LV and Kovacs K: Role of MGMT in tumor development,
progression, diagnosis, treatment and prognosis. Anticancer Res.
29:3759–3768. 2009.PubMed/NCBI
|
|
6
|
Fruehauf JP, Brem H, Brem S, Sloan A,
Barger G, Huang W and Parker R: In vitro drug response and
molecular markers associated with drug resistance in malignant
gliomas. Clin Cancer Res. 12:4523–4532. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hermisson M, Klumpp A, Wick W, et al:
O6-methylguanine DNA methyltransferase and p53 status
predict temozolomide sensitivity in human malignant glioma cells. J
Neurochem. 96:766–776. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Esteller M, Garcia-Foncillas J, Andion E,
et al: Inactivation of the DNA-repair gene MGMT and the clinical
response of gliomas to alkylating agents. N Engl J Med.
343:1350–1354. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hegi ME, Diserens AC, Gorlia T, et al:
MGMT gene silencing and benefit from temozolomide in glioblastoma.
N Engl J Med. 352:997–1003. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ignatova TN, Kukekov VG, Laywell ED,
Suslov ON, Vrionis FD and Steindler DA: Human cortical glial tumors
contain neural stem-like cells expressing astroglial and neuronal
markers in vitro. Glia. 39:193–206. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Singh SK, Hawkins C, Clarke ID, et al:
Identification of human brain tumour initiating cells. Nature.
432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kondo T, Setoguchi T and Taga T:
Persistence of a small subpopulation of cancer stem-like cells in
the C6 glioma cell line. Proc Natl Acad Sci USA. 101:781–786. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Eramo A, Ricci-Vitiani L, Zeuner A,
Pallini R, Lotti F, Sette G, Pilozzi E, Larocca LM, Peschle C and
De Maria R: Chemotherapy resistance of glioblastoma stem cells.
Cell Death Differ. 13:1238–1241. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Salmaggi A, Boiardi A, Gelati M, et al:
Glioblastoma-derived tumorospheres identify a population of tumor
stem-like cells with angiogenic potential and enhanced multidrug
resistance phenotype. Glia. 54:850–860. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jonasch E and Haluska FG: Interferon in
oncological practice: Review of interferon biology, clinical
applications, and toxicities. Oncologist. 6:34–55. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wakabayashi T, Natsume A, Hashizume Y,
Fujii M, Mizuno M and Yoshida J: A phase I clinical trial of
interferon-beta gene therapy for high-grade glioma: Novel findings
from gene expression profiling and autopsy. J Gene Med. 10:329–339.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Groves MD, Puduvalli VK, Gilbert MR, et
al: Two phase II trials of temozolomide with interferon-alpha2b
(pegylated and non-pegylated) in patients with recurrent
glioblastoma multi-forme. Br J Cancer. 101:615–620. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ohno M, Natsume A, Fujii M, Ito M and
Wakabayashi T: Interferon-beta, MCNU, and conventional radiotherapy
for pediatric patients with brainstem glioma. Pediatr Blood Cancer.
53:37–41. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Warren K, Bent R, Wolters PL, et al: A
phase 2 study of pegylated interferon α-2b (PEG-Intron®)
in children with diffuse intrinsic pontine glioma. Cancer.
118:3607–3613. 2012. View Article : Google Scholar :
|
|
20
|
Natsume A, Ishii D, Wakabayashi T, et al:
IFN-beta down-regulates the expression of DNA repair gene MGMT and
sensitizes resistant glioma cells to temozolomide. Cancer Res.
65:7573–7579. 2005.PubMed/NCBI
|
|
21
|
Natsume A, Wakabayashi T, Ishii D, et al:
A combination of IFN-beta and temozolomide in human glioma
xenograft models: Implication of p53-mediated MGMT downregulation.
Cancer Chemother Pharmacol. 61:653–659. 2008. View Article : Google Scholar
|
|
22
|
Lavon I, Fuchs D, Zrihan D, et al: Novel
mechanism whereby nuclear factor kappaB mediates DNA damage repair
through regulation of
O6-methylguanine-DNA-methyltransferase. Cancer Res.
67:8952–8959. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu G, Yuan X, Zeng Z, et al: Analysis of
gene expression and chemoresistance of CD133+ cancer
stem cells in glioblastoma. Mol Cancer. 5:672006. View Article : Google Scholar
|
|
24
|
Qiu ZK, Shen D, Chen YS, et al: Enhanced
MGMT expression contributes to temozolomide resistance in glioma
stem-like cells. Chin J Cancer. 33:115–122. 2014. View Article : Google Scholar :
|
|
25
|
Tubbs JL, Pegg AE and Tainer JA: DNA
binding, nucleotide flipping, and the helix-turn-helix motif in
base repair by O6-alkylguanine-DNA alkyltransferase and
its implications for cancer chemotherapy. DNA Repair. 6:1100–1115.
2007. View Article : Google Scholar
|
|
26
|
Chen ZP, Yarosh D, Garcia Y, et al:
Relationship between O6-methylguanine-DNA
methyltransferase levels and clinical response induced by
chloroethylnitrosourea therapy in glioma patients. Can J Neurol
Sci. 26:104–109. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Paz MF, Yaya-Tur R, Rojas-Marcos I, et al:
CpG island hyper-methylation of the DNA repair enzyme
methyltransferase predicts response to temozolomide in primary
gliomas. Clin Cancer Res. 10:4933–4938. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hegi ME, Liu L, Herman JG, et al:
Correlation of O6-methylguanine methyltransferase (MGMT)
promoter methylation with clinical outcomes in glioblastoma and
clinical strategies to modulate MGMT activity. J Clin Oncol.
26:4189–4199. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Colman H1, Berkey BA, Maor MH, et al
Radiation Therapy Oncology Group: Phase II Radiation Therapy
Oncology Group trial of conventional radiation therapy followed by
treatment with recombinant interferon-beta for supratentorial
glioblas-toma: Results of RTOG 9710. Int J Radiat Oncol Biol Phys.
66:818–824. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Motomura K, Natsume A, Kishida Y, et al:
Benefits of interferon-β and temozolomide combination therapy for
newly diagnosed primary glioblastoma with the unmethylated MGMT
promoter: A multicenter study. Cancer. 117:1721–1730. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Saccani S, Marazzi I, Beg AA and Natoli G:
Degradation of promoter-bound p65/RelA is essential for the prompt
termination of the nuclear factor kappaB response. J Exp Med.
200:107–113. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sethi G, Ahn KS, Sung B and Aggarwal BB:
Pinitol targets nuclear factor-kappaB activation pathway leading to
inhibition of gene products associated with proliferation,
apoptosis, invasion, and angiogenesis. Mol Cancer Ther.
7:1604–1614. 2008. View Article : Google Scholar : PubMed/NCBI
|
